U.S. PRODUCERS' QUESTIONNAIRE

POTASSIUM PERMANGANATE FROM CHINA

This questionnaire must be received by the Commission by <u>August 13, 2021</u>

See last page for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its review of the antidumping duty order concerning potassium permanganate from China (Inv. No. 731-TA-125 (Fifth Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Name of firm

| City | | | State | | Zip Code | | |
|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| Website _ | | | | | | | |
| Has your fir 2015? | m produced រុ | ootassium permang | ganate (as define | d on the | next page | at any time sin | ce January 1 |
| ☐ NO | (Sign the c | ertification below an | d promptly return | only this p | age of the | questionnaire to t | he Commissio |
| YES | (Complete | all parts of the ques | tionnaire, and retu | n the ent | ire questio | naire to the Com | mission) |
| nttps://arc | puox.usitc. | gov/oinv/ (PIN: P | ZERIVI) | | | | |
| e and belief | and underst | ein supplied in re and that the inform | mation submitted | question d is subje | ct to aud | it and verificati | on by the C |
| e and belief this certific on provided by the Com- ersigned, ac g or other p (a) for deve and evaluati 3; or (ii) by (| and understontion I also in this quest mission on the knowledge to roceedings in loping or moons relating U.S. governm | | esponse to this mation submitted the Commission oughout this product that produced in respondent to the condition of this or a factor of this or a factor of the contract persond the contract person the contract | question d is subje n, and i ceeding conse to y the Co related p | ect to aud ts employ in any ot this requ mmission proceeding ions of th | it and verificating and control of the control of t | on by the Co act personn ry proceedir ation and the and Offices and investig including u |
| e and belief this certific on provided by the Com- ersigned, ac g or other p (a) for deve and evaluati 3; or (ii) by (| and understo ation I also in this quest mission on th knowledge to roceedings n loping or mo ons relating J.S. governm sign approp | and that the information of the consent formation of the consent formation of the consent formation of the consent formation of the programs on the programs on the programs on the programs of the programs o | esponse to this mation submitted in the Commission oughout this product the commission of the contract personal agreements. | question d is subje n, and i ceeding conse to y the Co related p | ect to aud ts employ in any ot this requ mmission proceeding ions of th | it and verificating and control of the control of t | on by the Co act personn ry proceedir ation and the and Offices and investig including u |

PART I.—GENERAL INFORMATION

Background.-- On January 31, 1984, the Department of Commerce ("Commerce") issued an antidumping duty order on imports of potassium permanganate from China. On February 1, 2021, the Commission instituted a review pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. § 1675(c)) (the Act) to determine whether revocation of the order would be likely to lead to continuation or recurrence of material injury to the domestic industry within a reasonably foreseeable time. If both the Commission and Commerce make an affirmative determination, the order will remain in place. If either the Commission or Commerce makes a negative determination, Commerce will revoke the order. Questionnaires and other information pertinent to this proceeding are available at: https://www.usitc.gov/investigations/701731/2021/potassium_permanganate_china/fifth_review_full.htm

<u>Potassium permanganate</u> covered by this review is an inorganic chemical with the formula KMnO₄. It is produced in free-flowing, technical, and pharmaceutical grades.

Potassium permanganate is currently classifiable under subheading 2841.61.00 of the Harmonized Tariff Schedule of the United States (HTSUS). The HTSUS provisions are for convenience and customs purposes; the written description of the scope is dispositive.

Reporting of information.--If information is not readily available from your records in exactly the form requested, furnish carefully prepared estimates. If your firm is completing more than one questionnaire in connection with this proceeding (i.e., a producer, importer, and/or purchaser questionnaire), you need not respond to duplicated questions in the questionnaires.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

Verification.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all of your files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

Release of information.--The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals.

<u>D-GRIDS tool.</u>--The Commission has a tool that firms can use to move data from their own MS Excel compilation files into self-contained data tables within this MS Word questionnaire, thereby reducing the amount of cell-by-cell data entry that would be required to complete this form. This tool is a macroenabled MS Excel file available for download from the Commission's generic questionnaires webpage (https://www.usitc.gov/trade_remedy/question.htm) called the "D-GRIDs tool." Use of this tool to help your firm complete this questionnaire is *optional*. Firms opting to use the D-GRIDs tool to populate their data into this questionnaire will need the D-GRIDs specification sheet PDF file specific to this proceeding (available on the case page which is linked under the "Background" above) which includes the necessary references relating to this questionnaire, as well as the macro-enable MS Excel D-GRIDs tool itself from the generic questionnaires page. More detailed instructions on how to use the D-GRIDs tool are available within the D-GRIDs tool itself.

I-1. <u>OMB statistics</u>.--Please report below the actual number of hours required and the cost to your firm of completing this questionnaire.

| Hours | Dollars |
|-------|---------|
| | |

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please attach such comments to your response or send to the Office of Investigations, USITC, 500 E St. SW, Washington, DC 20436.

| I-2a. | Establishments coveredProvide the city, state, zip code, and brief description of each |
|-------|------------------------------------------------------------------------------------------|
| | establishment covered by this questionnaire. Firms operating more than one establishment |
| | should combine the data for all establishments into a single report. |

"<u>Establishment</u>"--Each facility of a firm involved in the <u>production</u> of potassium permanganate, including auxiliary facilities operated in conjunction with (whether or not physically separate from) such facilities.

| Establishments Covered ¹ | City, State | Zip (5 digit) | Description |
|----------------------------------------|------------------------------|---------------------------|-------------|
| 1 | | | |
| 2 | | | |
| 3 | | | |
| 4 | | | |
| 5 | | | |
| 6 | | | |
| ¹ Additional discu | ussion on establishments con | solidated in this questic | onnaire: |

| I-2b. | - | nation If your firm or parent firm is publicly traded, please specify the trading symbol: |
|-------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| I-2c. | · | f your firm or parent firm is represented by external counsel in relation to use specify the name of the law firm and the lead attorney(s). |
| | Law firm: | |
| | Lead attorney(s): | |

I-3. <u>Position regarding continuation of order.</u>—Does your firm support or oppose continuation of the following antidumping duty order currently in place for potassium permanganate?

| Country | Order type | Support | Oppose | Take no position |
|---------|------------------|---------|--------|------------------|
| China | Antidumping duty | | | |

U.S. Producers' Questionnaire – Potassium Permanganate (Fifth Review) I-4. Ownership.--Is your firm owned, in whole or in part, by any other firm? No Yes--List the following information, relating to the ultimate parent/owner. **Extent of** ownership Firm name (percent) Country I-5. Related importers/exporters.--Does your firm have any related firms, either domestic or foreign, that are engaged in importing potassium permanganate into the United States or that are engaged in exporting potassium permanganate to the United States? Yes--List the following information. No Firm name **Affiliation** Country

| Firm na | me | Country | Affiliation |
|------------------------------|-----------------------------------------------------------|-------------------------------|-----------------------------------------------------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | se discuss trends | | es of potassium permanganate to contracted, or remained the sam |
| a) Pleas mark b) Pleas | se discuss trends ets since 2015. se discuss your p | Has this production expanded, | |

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Nitin Joshi (202-708-1669, Nitin.Joshi@usitc.gov). **Supply all data requested on a** <u>calendar-year</u> **basis**.

| II-1. | Contact inform | <u>Contact information</u> Please identify the responsible individual and the manner by which | | | | | |
|-------|----------------|-----------------------------------------------------------------------------------------------|--|---|--|--|--|
| | Commission st | Commission staff may contact that individual regarding the confidential information submitted | | | | | |
| | in part II. | | | | | | |
| | | | | _ | | | |
| | Name | | | | | | |
| | Title | | | | | | |
| | Email | | | | | | |
| | Telephone | | | | | | |

II-2a. <u>Changes in operations.</u>—Please indicate whether your firm has experienced any of the following changes in relation to the production of potassium permanganate since January 1, 2015.

| Chec | k as many as appropriate. | If checked, please describe the nature, date(s), and significance of any such reported changes as well as the business reasons for them; leave completely blank if not applicable |
|------|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Plant openings | |
| | Plant closings | |
| | Relocations | |
| | Expansions | |
| | Acquisitions | |
| | Consolidations | |
| | Prolonged shutdowns or production curtailments | |
| | Revised labor agreements | |
| | Other (e.g., technology) | |

| II -2b | Anticipated changes in operations. — Does your firm anticipate any changes in in the character |
|--------|------------------------------------------------------------------------------------------------|
| | of its operations or organization relating to the production of potassium permanganate in the |
| | future? |

| No | Yes | If yes, supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentations that address this issue. |
|----|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | |

II-2c. COVID-19 pandemic.--Since January 1, 2020, has the COVID-19 pandemic or have any government actions taken to contain the spread of the COVID-19 virus resulted in changes in relation to your firm's supply chain arrangements, production, employment, and shipments relating to potassium permanganate?

| No | If yes, describe these changes including a separate discussion of the (a) supply chain impact, (b) production and shipments impact, and (c) employment impact of the COVID-19 pandemic. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | |

II-3a. **Production using same machinery.**-- Please report your firm's production of products made using the same equipment, machinery, or employees as used to produce potassium permanganate, and the combined production capacity on this shared equipment, machinery, or employees in the periods indicated.

"Overall production capacity" or "capacity" – The level of production that your establishment(s) could reasonably have expected to attain during the specified periods. Assume normal operating conditions (i.e., using equipment and machinery in place and ready to operate; normal operating levels (hours per week/weeks per year) and time for downtime, maintenance, repair, and cleanup).

Note.--If your firm does not produce any out-of-scope merchandise on the same machinery and equipment as scope merchandise then the "overall production capacity" numbers reported in this question should be exactly equal to the "average production capacity" numbers reported in question II-4. If, however, your firm does produce out-of-scope merchandise using the same machinery and equipment as scope merchandise, then the "average production capacity" reported in question II-4 should exclude the portion of "overall production capacity" that was used to produce this out-of-scope merchandise.

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

| Quantity (in 1,000 pounds) | | | | | |
|------------------------------------------|------|------|------|--------|------|
| Calendar year January- | | | | y-June | |
| Item | 2018 | 2019 | 2020 | 2020 | 2021 |
| Overall production capacity ¹ | | | | | |
| Production of: | | | | | |
| Potassium permanganate ² | 0 | 0 | 0 | 0 | 0 |
| Other products ³ | | | | | |
| Total production using same | | | | | |
| machinery or workers | 0 | 0 | 0 | 0 | 0 |

¹ Data reported for capacity (first line) should be greater than data reported for total production (last line).

² Data entered for production of potassium permanganate will populate here once reported in question II-4a.

³ Please identify these products: .

| U.S. Producers' Questionnaire – Potassium Permanganate (Fifth Review) | |
|-----------------------------------------------------------------------|--|
|-----------------------------------------------------------------------|--|

| H | lours per w | veek | Weeks per year | | |
|------------------------------------------------|------------------------------------------------------|-------------------------|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|----------|
| - | | | escribe the methodology uppersonance in report | | roductio |
| . , | <u>'</u> | • | , , , | | |
| | | | | | |
| | on constrai | | describe the constraint(s |) that set the limit(s) on y | our firm |
| | JII Cabacity | • | | | |
| p. 0 0. 0. 0. | | | | | |
| P • • • • • • • • • • • • • • • • • • • | | | | | |
| | | | | | |
| | shifting.— | | | | |
| Product s | shifting.— | able to swit | ch production (capacity) k | notwoon notacsium norm | anganat |
| Product s | shifting.— | | ch production (capacity) k e same equipment and/oi | | anganat |
| Product s | shifting.— | cts using the | e same equipment and/or | labor? | |
| Product s | shifting.— | cts using the | | r labor? roducts or are able to pro | |
| Product s | shifting.— s your firm other produ | cts using the | e same equipment and/or | r labor? roducts or are able to pro | |
| Product s (i) Is O | shifting.— s your firm other produ | If yes—(i.e products) I | e same equipment and/or ., have produced other properties of the produced other produced other actuments. | r labor? roducts or are able to pro al or potential products: | oduce ot |
| Product s (i) Is No (ii) P | shifting.— s your firm ther produ Yes Clease descr | If yes—(i.e products) I | e same equipment and/or | roducts or are able to pro al or potential products: | oduce ot |

- II-4a. <u>Production, shipment, and inventory data</u>.--Report your firm's production capacity, production, shipments, and inventories related to the production of potassium permanganate in its U.S. establishment(s) during the specified periods.
 - "Average production capacity" or "capacity" The level of production that your establishment(s) could reasonably have expected to attain during the specified periods. Assume normal operating conditions (i.e., using equipment and machinery in place and ready to operate; normal operating levels (hours per week/weeks per year) and time for downtime, maintenance, repair, and cleanup; and a typical or representative product mix).
 - "**Production**" All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.
 - "Commercial U.S. shipments" Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report <u>net values</u> (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.
 - "Internal consumption" Product consumed internally by your firm. Such transactions are valued at fair market value.
 - "Transfers to related firms" Shipments made to related firms. Such transactions are valued at fair market value.
 - "Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.
 - "Export shipments" Shipments to destinations outside the United States, including shipments to related firms.
 - "Inventories" Finished goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-4a. Production, shipment, and inventory data. --Continued

| Quan | tity (<i>in 1,000</i>) | <i>pounds</i>) and v | alue (<i>in \$1,000</i> |)) | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-----------------------|--------------------------|---------------------------------------------------------------------------|--------------------------------|
| | Calendar year | | | Januar | y-June |
| Item | 2018 | 2019 | 2020 | 2020 | 2021 |
| Average production capacity ¹ (Quantity) (A) | | | | | |
| Beginning-of-period inventories (Quantity) (B) | | | | | |
| Production (Quantity) (C) | | | | | |
| U.S. shipments: Commercial shipments: Quantity (D) | | | | | |
| Value (E) | | | | | |
| Internal consumption: ² Quantity (F) | | | | | |
| Value (G) | | | | | |
| Transfers to related firms: ² Quantity (H) | | | | | |
| Value (I) | | | | | |
| Export shipments: ³ Quantity (J) | | | | | |
| Value (K) | | | | | |
| End-of-period inventories (Quantity) (L) | | | | | |
| The production capacity reported is methodology used to calculate production necessary). Internal consumption and trans different basis for valuing these transprovide the data above at fair marke | on capacity, and e fers to related f sactions, please | irms must be va | es in reported cap | acity (use additional acity (use additional acity (use additional acity)) | al pages as your firm use a |

Production, shipment, and inventory data.--Continued II-4a.

RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY.--Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather reflect your firm's actual records; and, also provide explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

| Item | Calendar year | | | January-June | | |
|------------------------------------------------------------------------------------------------------------------|---------------|------|------|--------------|------|--|
| | 2018 | 2019 | 2020 | 2020 | 2021 | |
| B + C - D - F - H - J - L = should equal zero ("0") or provide an explanation. ¹ | 0 | 0 | 0 | 0 | 0 | |
| ¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are | | | | | | |

nonetheless accurate:

II-4b. Historical U.S. shipment data. -- Report the quantity and value of your firm's U.S. shipments (including commercial U.S. shipments, internal consumption, and transfers, but not including exports) of potassium permanganate produced in your U.S. establishment(s) during the specified periods.

| Quantity (in 1,000 pounds), Value (in \$1,000) | | | | |
|------------------------------------------------|------|------|------|--|
| Item | 2015 | 2016 | 2017 | |
| U.S. shipments Quantity | | | | |
| Value | | | | |

II-5. <u>U.S. shipments by grade</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) by grade during the specified periods.

| | Quantity (in 1,000 | pounds) and va | alue (<i>in \$1,000</i>) | | | |
|------------------------------------------------|------------------------|----------------|----------------------------|--------------|------|--|
| Item | Calendar year | | | January-June | | |
| | 2018 | 2019 | 2020 | 2020 | 2021 | |
| Free-flowing grade: Quantity (M) | | | | | | |
| Value (N) | | | | | | |
| Technical grade: Quantity (O) | | | | | | |
| Value (P) | | | | | | |
| Pharmaceutical grade: Quantity (Q) | | | | | | |
| Value (R) | | | | | | |
| Other grades: ¹ Quantity (S) | | | | | | |
| Value (T) | | | | | | |
| ¹ Please describe these other grade | es of potassium perman | ganate: | | | | |

<u>RECONCILIATION OF SHIPMENTS</u>.--Please ensure that the quantities and values reported for channels of U.S. shipments by grade (i.e., lines M through T) in each time period equal the quantity reported for U.S shipments (i.e., lines D though I) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| Reconciliation item | Calendar year | | | January-June | | |
|-------------------------------------------|---------------|------|------|--------------|------|--|
| | 2018 | 2019 | 2020 | 2020 | 2021 | |
| <i>Quantity:</i> M + O + Q + S + U – D – | | | | | | |
| F - H = zero ("0"), if not revise. | 0 | 0 | 0 | 0 | 0 | |
| <i>Value:</i> N + P + R + T – E – G – I = | | | | | | |
| zero ("0"), if not revise. | 0 | 0 | 0 | 0 | 0 | |

II-6. <u>Channels of distribution</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) during the specified periods by channel of distribution.

| | Quantit | y (in 1,000 pour | nds) | | |
|---------------------------------------------------------------|---------|------------------|------|------|--------|
| Item Calendar year January-June | | | | | y-June |
| | 2018 | 2019 | 2020 | 2020 | 2021 |
| Channels of distribution: U.S. shipments— to distributors (U) | | | | | |
| to end users (V) | | | | | |

<u>RECONCILIATION OF CHANNELS</u>.--Please ensure that the quantities reported for channels of distribution (i.e., lines U and V) in each time period equal the quantity reported for U.S shipments (i.e., lines D, F, and H) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| Reconciliation item | Calendar year | | | January-June | | |
|------------------------------------|---------------|------|------|--------------|------|--|
| | 2018 | 2019 | 2020 | 2020 | 2021 | |
| U + V - D - F - H = zero ("0"), if | | | | | | |
| not revise. | 0 | 0 | 0 | 0 | 0 | |

II-7. <u>Employment data</u>.--Report your firm's employment-related data related to the production of potassium permanganate and provide an explanation for any trends in these data.

"Production and Related Workers" (PRWs) includes working supervisors and all nonsupervisory workers (including group leaders and trainees) engaged in fabricating, processing, assembling, inspecting, receiving, storage, handling, packing, warehousing, shipping, trucking, hauling, maintenance, repair, janitorial and guard services, product development, auxiliary production for plant's own use (e.g., power plant), recordkeeping, and other services closely associated with the above production operations.

Average number employed may be computed by adding the number of employees, both full time and part time, for the 12 pay periods ending closest to the 15th of the month and divide that total by 12.

For the January to June periods, calculate similarly and divide by 6. If your firm had the same number of PRWs in all calendar year and had not experienced any changes in PRWs in the most recent interim period, you would have the same number of PRWs for the interim periods, regardless of whether the interim periods are Jan-Mar (Q1), Jan-June (Q1+Q2), or Jan-Sept (Q1+Q2+Q3)."

"Hours worked" includes time paid for sick leave, holidays, and vacation time. Include overtime hours actually worked; do not convert overtime pay to its equivalent in straight time hours.

"Wages paid" – Total wages paid before deductions of any kind (e.g., withholding taxes, old-age and unemployment insurance, group insurance, union dues, bonds, etc.). Include wages paid directly by your firm for overtime, holidays, vacations, and sick leave.

| Item | Calendar year | | January-June | | |
|-------------------------------------------------------|---------------|------|--------------|------|------|
| | 2018 | 2019 | 2020 | 2020 | 2021 |
| Employment data: Average number of PRWs (number) (AM) | | | | | |
| Hours worked by PRWs (1,000 hours) (AN) | | | | | |
| Wages paid to PRWs (\$1,000) (AO) | | | | | |

| Explanation of trends: |
|------------------------|
| |
| |
| |
| |

Transfers to related firms.--If your firm reported transfers to related firms in question II-4,

please identify the firm(s) and indicate the nature of the relationship between your firm and the

II-8.

| | market va | lue or by | a non-r | market formul | a, whether you | ur firm retaine | the transfers w d marketing rig sources other t | thts to all |
|------------------------|-----------------------------------|---------------------------|------------------|----------------------------------|------------------------------------|---------------------------------|--------------------------------------------------------------------|-------------|
| | | | | | | | | |
| II-9. | in other co | ountries si of record. | ince Jai | nuary 1, 2015? should be repo | ? (Do not inclu orted in an imp | de imports fo porter questio | uced in the Uni r which your fir nnaire). ity such as ano | m was the |
| | producer, | a U.S. dis | tributo | r, or a U.S. firr | n that has dire | ctly imported | • | |
| | No | Yes | | Report such our firms' purc | • | the table belo | w and explain | the reasons |
| | | | | | | | | |
| | either for | your own | accour | nt or as a servi | ce for another | entity, those | from foreign s purchases are t the table belov | o be |
| | | | | Quantity | (in 1,000 pour | - | 1 | |
| | Ite | m | | | Calendar year | 1 | Januar | • |
| of pot from- Chi | na | manganat | | 2018 | 2019 | 2020 | 2020 | 2021 |
| - | other source | | | | | 1 | | |
| produ | ases from d Icers ² | iomestic | | | | | | |
| Purch | ases from o | other sour | ces ³ | | | | | |
| | | | - | | | | oduct. If your firr | n's import |
| | - | - | | • | for each listed s | | is product: | |
| | | | - | | our firm purcha | - | | <u>-</u> |

| II S | Producers' | Ouestionnaire - | - Potassium | Permanganate | (Fifth Review) |
|------|------------|-----------------|--------------|---------------|-------------------|
| U.J. | FIUUULEIS | Questionnane - | r Otassiuiii | reminantament | II II LII IVEVIEW |

| II_10 | IIS imports. | Since lanuary | 1 2015 | has vour firm | imported | notaccium | permanganate? |
|--------|---------------|-----------------|----------|---------------|----------|-------------|---------------|
| II-TU. | U.S. Imports. | Since January . | T. ZUTD. | nas vour urm | imported | DOLASSIUITI | permanganate: |

"Importer" – The person or firm primarily liable for the payment of any duties on the merchandise, or an authorized agent acting on his behalf.

| No | Yes | |
|----|-----|-------------------------------------------------------------------|
| | | If yes <u>COMPLETE AND RETURN A U.S. IMPORTERS' QUESTIONNAIRE</u> |

II-11. <u>Toll production</u>.--Since January 1, 2015, has your firm been involved in a toll agreement regarding the production of potassium permanganate?

"Toll agreement"--Agreement between two firms whereby the first firm furnishes the raw materials and the second firm uses the raw materials to produce a product that it then returns to the first firm with a charge for processing costs, overhead, etc.

| No | Yes | If yes Please describe the toll arrangement(s) and name the firm(s) involved. |
|----|-----|-------------------------------------------------------------------------------|
| | | |

II-12. Foreign trade zones.--

(a) <u>Firm's FTZ operations</u>.--Does your firm produce potassium permanganate in and/or admit potassium permanganate into a foreign trade zone (FTZ)?

"Foreign trade zone" is a designated location in the United States where firms utilize special procedures that allow delayed or reduced customs duty payments on foreign merchandise. A foreign trade zone must be designated as such pursuant to the rules and procedures set forth in the Foreign-Trade Zones Act.

| No | If yes Describe the nature of your firms operations in FTZs and identify the specific FTZ site(s). |
|----|----------------------------------------------------------------------------------------------------|
| | |

(b) Other firms' FTZ operations.--To your knowledge, do any firms in the United States import potassium permanganate into a foreign trade zone (FTZ) for use in distribution of potassium permanganate and/or the production of downstream articles?

| No | Yes | If yesIdentify the firms and the FTZs. |
|----|-----|----------------------------------------|
| | | |

| l-13. | imports of p capacity, pro profits, cash | otassium po oduction, U flow, capita | be the significance of the existing antidumping duty order covering ermanganate from China in terms of its effect on your firm's production a.S. shipments, inventories, purchases, employment, revenues, costs, all expenditures, research and development expenditures, and asset to compare your firm's operations before and after the imposition of the |
|----------------|------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| l -14 . | operations of inventories, research and | or organizat purchases, d developm ate in the fu | tionWould your firm anticipate any changes in the character of its ion, including its production capacity, production, U.S. shipments, employment, revenues, costs, profits, cash flow, capital expenditures, ent expenditures, or asset values relating to the production of potassium ture if the antidumping duty order on potassium permanganate from ed? |
| | No | Yes | If yes, supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentations that address this issue. |
| | | | |
| -15. | for which a rexplanation | narrative bo in the space providing th | your firm would like to explain further a response to a question in Part II ox was not provided, please note the question number and the e provided below. Please also use this space to highlight any issues your e data in this section, including but not limited to technical issues with naire. |

PART III.--FINANCIAL INFORMATION

| Address questions on this part of the questionnaire to Jennifer Catalano (| (202-205-2056, |
|----------------------------------------------------------------------------|----------------|
| Jennifer.Catalano@usitc.gov) or Charles Yost (202-708-1445, Charles.yos | t1@usitc.gov) |

| | in par | |
|-----|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Name | |
| | Title Email | |
| | Teleph | hone |
| -2. | Accou | unting systemBriefly describe your firm's financial accounting system. |
| | A. | When does your firm's fiscal year end (month and day)? If your firm's fiscal year changed during the data-collection period, explain below: |
| | [| NotePlease report all financial data in part III on a calendar year basis. |
| | B.1. | Describe the lowest level of operations (e.g., plant, division, company-wide) for which financial statements are prepared that include potassium permanganate: |
| | 2. | Does your firm prepare profit/loss statements for potassium permanganate: Yes No |
| | 3. | How often did your firm (or parent company) prepare financial statements (including annual reports, 10Ks)? Please check relevant items below. Audited, unaudited, annual reports, 10Ks, 10 Qs, Monthly, quarterly, semi-annually, annually |
| | 4. | Accounting basis: U.S. GAAP, IFRS, cash, tax, or other comprehensive basis of accounting (specify) |
| | | Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the financial data, as Commission staff may contact your firm regarding questions on the financial data. The Commission may also request that your company submit copies of the supporting documents/records (financial statements, including internal profit-and-loss statements for the division or product group that includes potassium permanganate, as well as specific statements and worksheets) used to compile these data. |
| | | accounting systemBriefly describe your firm's cost accounting system (e.g., standard |
| -3. | Cost a | briefly describe your firm's cost decounting system (e.g., standard |

| | interest expense and other in | | | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------|--|--|--|--|--|--|
| • | <u>Product listing.</u> Please list the products your firm produces in the facilities in which it produces potassium permanganate, and provide the share of net sales accounted for by these products in your firm's most recent fiscal year. | | | | | | | | |
| | Products | | Share of sales | | | | | | |
| | Potassium permanganate | | % | | | | | | |
| | | | % | | | | | | |
| | | | % | | | | | | |
| | | | % | | | | | | |
| | | | % | | | | | | |
| | · · · · · · · · · · · · · · · · · · · | nanganate from any related supp firms, divisions and/or other com | nponents within the same | | | | | | |
| a. | Inputs from related suppliersPlease identify the inputs used in the production of potassium permanganate that your firm purchases from related suppliers and that are reflected in question III-9a. For "Share of total COGS" please report this information by relevant input on the basis of your most recently completed fiscal year. For "Input valuation" please describe the basis, as recorded in the company's own accounting system, of the purchase cost from the related supplier; e.g., the related supplier's actual cost, cost plus, negotiated transfer price to approximate fair market value. | | | | | | | | |
| | | 2. | | | | | | | |
| | | Related supplier | Share of total CO | | | | | | |

| III-7b. | <u>Inputs from related suppliers at cost</u> Please confirm that the inputs purchased from related |
|---------|----------------------------------------------------------------------------------------------------|
| | suppliers, as identified in III-7, were reported in III-9a (financial results on potassium |
| | permanganate) in a manner consistent with the firm's accounting books and records. |

| Yes | No | If noIn the space below, please report the valuation basis of inputs purchased from related suppliers as reported in question III-9a.: |
|-----|----|----------------------------------------------------------------------------------------------------------------------------------------|
| | | |

| III-8. | Additional products: potassium permanganate producers.—Identify whether your firm |
|--------|--------------------------------------------------------------------------------------------------|
| | realized revenues from the sales of any additional products (e.g., by-products or co-products) |
| | produced during the course of producing potassium permanganate: |
| | Co-Product :; identify the co-product and whether or not revenues and costs are included in |
| | question III-9a: |
| | By-Product |
| | If your answer is "By-Product," report the revenues associated with the sale or transfer of such |
| | by-products for your firm's three most recently completed calendar years, and for the specified |

by-products for your firm's three most recently completed calendar years, and for the specified interim periods. Note: the data provided below will appear in question III-9a as a reduction to COGS.

| Value (in \$1000) | | | | | | | |
|----------------------------------------|--------------------------|--|--|--|--------|--|--|
| Calendar year January-June | | | | | y-June | | |
| Item | 2018 2019 2020 2020 2021 | | | | 2021 | | |
| By-product sales revenue ¹² | | | | | | | |

¹ Please identify the by-products in question

² Please describe how your firm classifies these by-product revenues in the normal course of business (e.g., included in net sales values, as a reduction to COGS, included in "all other income").

III-9a. Operations on potassium permanganate.--Report the revenue and related cost information requested below on the potassium permanganate operations of your firm's U.S. establishment(s).¹ Do not report resales of products. Note that internal consumption and transfers to related firms must be valued at fair market value. Input purchases from related suppliers should be consistent with and based on information in the firm's accounting books and records. Provide data for your firm's three most recently completed calendar years, and for the specified interim periods. If your firm was involved in tolling operations (either as the toller or as the tollee), please contact Jennifer Catalano at (202) 205-2056 or Charles Yost at (202) 708-1445 before completing this section of the questionnaire.

| | Quantity (in 1,000 | 0 pounds) and val | ue (<i>in \$1,000</i>) | | | |
|------------------------------------------------------------|--------------------|-------------------|--------------------------|--------------|------|--|
| | Calendar year | | | January-June | | |
| Item | 2018 | 2019 | 2020 | 2020 | 2021 | |
| Net sales quantities: ² Commercial sales ("CS") | | | | | | |
| Internal consumption ("IC") | | | | | | |
| Transfers to related firms ("Transfers") | | | | | | |
| Total net sales quantities | 0 | 0 | 0 | 0 | C | |
| Net sales values: ² Commercial sales | | | | | | |
| Internal consumption | | | | | | |
| Transfers to related firms | | | | | | |
| Total net sales values | 0 | 0 | 0 | 0 | C | |
| Cost of goods sold (COGS): ³ Raw materials | | | | | | |
| Direct labor | | | | | | |
| Other factory costs | | | | | | |
| Less: by-product revenue | 0 | 0 | 0 | 0 | C | |
| Total COGS | 0 | 0 | 0 | 0 | C | |
| Gross profit or (loss) | 0 | 0 | 0 | 0 | C | |
| Selling, general, and administrative (SG&A) expenses: | | | | | | |
| Operating income (loss) | 0 | 0 | 0 | 0 | C | |
| Other expenses and income: Interest expense | | | | | | |
| All other expense items | | | | | | |
| All other income items | | | | | | |
| Net income or (loss) before income taxes | 0 | 0 | 0 | 0 | C | |
| Depreciation/amortization included above | | | | | | |

¹ Include only sales (whether <u>domestic or export</u>) and costs related to your <u>U.S. manufacturing operations</u>.

Note -- The table above contains calculations that will appear when you have entered data in the MS Word form fields.

² Less discounts, returns, allowances, and prepaid freight. Sales shoujld be reported on an f.o.b. point of shipment basis. If your firm sells on a delivered basis, deducty the freight from both sales and costs. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

³ COGS (whether for domestic or export sales) should include costs associated with CS, IC, and Transfers.

| quan incor calcu | I data reconciliationThe calculable line items from question III-9a (i.e., total net sales ies and values, total COGS, gross profit (or loss), operating income (or loss), and net (or loss)) have been calculated from the data submitted in the other line items. Do the ted fields return the correct data according to your firm's financial records ignoring non all differences that may arise due to rounding? | 9 |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Y | NoIf the calculated fields do not show the correct data, please double check the feeder data for data entry errors and revise. | ıe |
| | Also, check signs accorded to the post operating income line items; the twe expense line items should report positive numbers (i.e., expenses are positive and incomes or reversals are negativeinstances of the latter should be rare in those lines) while the income line item also in most instances should have its value be a positive number (i.e., income is positive expenses or reversals are negative). | |
| | If after reviewing and potentially revising the feeder data your firm has provided, the differences between your records and the calculated fields persist please identify and discuss the differences in the space below. | |
| | | |

III-9c. Raw materials.--Please report the values of total raw material costs reported in III-9a for the specified calendar years and interim periods:

| | Value (in \$1,000) | | | | | Procurement method | |
|------------------------------------------------------------------------------------------------------|--------------------|------|--------------|------|---------------------|------------------------|--|
| | Calendar year | | January-June | | Produced by your | Purchased by your firm | |
| Input | 2018 | 2019 | 2020 | 2020 | 2021 | firm | |
| Potassium hydroxide | | | | | | | |
| Manganese dioxide | | | | | | | |
| Other material inputs ¹ | | | | | | | |
| Total raw materials | 0 | 0 | 0 | 0 | 0 | | |
| ¹ Please indicate any other notable "other" raw materials not expressly identified above: | | | | | | | |

<u>RECONCILIATION OF RAW MATERIALS.</u>--Please ensure that the values reported raw materials in this question equal the values reported for raw materials in question III-9a in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | | January-June | |
|-----------------------------------------|---------------|------|------|--------------|------|
| Reconciliation | 2018 | 2019 | 2020 | 2020 | 2021 |
| Raw materials from this question III-9c | | | | | |
| less raw materials in question III-9a = | | | | | |
| zero ("0"), if not revise. | 0 | 0 | 0 | 0 | 0 |

III-10. Nonrecurring items (charges and gains) included in the subject product financial results.--For each annual and interim period for which financial results are reported in question III-9a, please specify all material (significant) nonrecurring items (charges and gains) in the schedule below, the specific question III-9a line item where the nonrecurring items are included, a brief description of the relevant nonrecurring items, and the associated values (in \$1,000), as reflected in question III-9a; i.e., if an aggregate nonrecurring item has been allocated to question III-9a, only the allocated value amount included in question III-9a should be reported in the schedule below. Note: The Commission's objective here is to gather information only on material (significant) nonrecurring items which impacted the reported financial results of the subject product in question III-9a.

| | Calendar year | | | Januar | y-June |
|---------------------|---------------|------|--------------------------|--------|--------|
| | 2018 | 2019 | 2020 | 2020 | 2021 |
| Item | | | Value (<i>\$1,000</i>) | | |
| Nonrecurring item 1 | | | | | |
| Nonrecurring item 2 | | | | | |
| Nonrecurring item 3 | | | | | |
| Nonrecurring item 4 | | | | | |
| Nonrecurring item 5 | | | | | |
| Nonrecurring item 6 | | | | | |
| Nonrecurring item 7 | | | | | |

Nonrecurring item: In this table please provide a brief description of each nonrecurring item reported above and indicate the specific line item in table III-9a where the nonrecurring item is classified.

| | Description of the nonrecurring item | Income statement classification of the nonrecurring item |
|---------------------|--------------------------------------|----------------------------------------------------------|
| Nonrecurring item 1 | | |
| Nonrecurring item 2 | | |
| Nonrecurring item 3 | | |
| Nonrecurring item 4 | | |
| Nonrecurring item 5 | | |
| Nonrecurring item 6 | | |
| Nonrecurring item 7 | | |

| III-11. | <u>Classification of identified nonrecurring items (charges and gains) in the accounting books and</u> records of the companyIf non-recurring items were reported in question III-10 above, please |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | identify where your company recorded these items in your accounting books and records in the normal course of business; i.e., just as responses to question III-10 identify where these items are reported in question III-9a. |
| | |

III-12. <u>Asset values</u>.--Report the <u>total</u> assets: both current assets such as cash, accounts receivable (net of allowances), inventory, etc; and long-term assets net of depreciation, intangible assets, and goodwill. These assets are associated with the production, warehousing, and sale of potassium permanganate. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for potassium permanganate in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with relevant cost allocations in question III-9a. Provide data as of the end of your firm's three most recently completed calendar years.

Note: Total assets should reflect <u>net assets</u> after any accumulated depreciation and allowances deducted.

Total assets should be <u>allocated to the subject products</u> if these assets are also related to other products. Please provide a <u>brief explanation if there are any substantial changes</u> in total asset value during the period; e.g., due to asset write-offs, revaluation, and major purchases.

| | | Value (in \$1,000) | |
|---------------------------------|---------------|--------------------|------|
| | Calendar year | | |
| Item | 2018 | 2019 | 2020 |
| Total assets (net) ¹ | | | |
| ¹ Describe | | | |

III-13. <u>Capital expenditures and research and development expenses.</u>—Report your firm's capital expenditures and research and development expenses for potassium permanganate. Provide data for your firm's three most recently completed calendar years, and for the specified interim periods.

| | | V | alue (<i>in \$1,000</i>) | | |
|------------------------------------------------|------|---------------|----------------------------|----------|------|
| | | Calendar year | | January- | June |
| Item | 2018 | 2019 | 2020 | 2020 | 2021 |
| Capital expenditures ¹ | | | | | |
| Research and development expenses ² | | | | | |

¹ Please describe the nature, focus, and significance of your firm's capital expenditures on the subject product. _____.

² Please describe the nature, focus, and significance of your firm's R&D expenses related to subject product. _____.

| U.S. Producers' | Questionnaire | Potassium | Permanganate | (Fifth | Review |
|-----------------|---------------|-------------------------------|--------------|--------|--------|
|-----------------|---------------|-------------------------------|--------------|--------|--------|

| III-14. | Data consistency and reconciliation. — Please note that we are requesting your firm's financial |
|---------|--------------------------------------------------------------------------------------------------------|
| | data for questions III-9a, III-12, and III-13 on a calendar year basis. Please confirm that your firm |
| | reported these data on a calendar-year basis:: |

| Yes | No | If no, please explain |
|-----|----|-----------------------|
| | | |

Please note the quantities and values reported in question III-9a should reconcile with the data reported in question II-4a (including export shipments) as long as they are reported on the same calendar year basis.

<u>RECONCILIATION OF TRADE VS FINANCIAL DATA.</u>--Please ensure that the quantities and values reported for total shipments in part II equal the quantities and values reported for total net sales in part III of this questionnaire in each time period. If the calculated fields below return values other than zero (i.e., "0") and both are being reported on a calendar basis, please explain the discrepancy below.

| | Calendar year data | | | January-June | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------|------|--------------|------|--|
| Reconciliation | 2018 | 2019 | 2020 | 2020 | 2021 | |
| Quantity: Trade data from question II-4a (lines D, F, H, and J) less financial total net sales quantity data from question III-9a, = zero ("0"). | 0 | 0 | 0 | 0 | 0 | |
| Value: Trade data from question II- 4a (lines E, G, I, and K) less financial total net sales value data from question III-9a, = zero ("0"). | 0 | 0 | 0 | 0 | 0 | |

Do these data in question III-9a reconcile with data in question II-4a?

| Yes | No | If no, please explain. |
|-----|----|------------------------|
| | | |

| III-15. | Other explanationsIf your firm would like to further explain a response to a question in Part III |
|---------|----------------------------------------------------------------------------------------------------|
| | for which a narrative box was not provided, please note the question number and the |
| | explanation in the space provided below. Please also use this space to highlight any issues your |
| | firm had in providing the data in this section, including but not limited to technical issues with |
| | the MS Word questionnaire. |

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Cindy Cohen (202-205-3230, cindy.cohen@usitc.gov).

IV-1. <u>Contact information.</u>--Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part IV.

| Name | |
|-----------|--|
| Title | |
| Email | |
| Telephone | |

PRICE DATA

IV-2. This question requests quarterly quantity and value data for your firm's commercial shipments to unrelated U.S. customers of the following products produced by your firm.

Product 1.-- Free-flowing grade potassium permanganate

Product 2.-- Technical grade potassium permanganate

Please note that values should be <u>f.o.b.</u>, <u>U.S.</u> <u>point of shipment</u> and should not include U.S.-inland transportation costs. Values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates).

(a) During January 2018-June 2021, did your firm produce and sell to unrelated U.S. customers any of the above listed products (or any products that were competitive with these products)?

| YesPlease complete the following pricing data table as appropriate. |
|---------------------------------------------------------------------|
| NoSkip to question IV-3. |

IV-2b. <u>Price data</u>.--Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

Report data in <u>actual pounds</u> (not 1,000 pounds) and <u>actual dollars</u> (not 1,000s).

| (Quantity in pounds, value in dollars) | | | | | |
|----------------------------------------|----------|----------------|-----------|-------|--|
| | Produ | ict 1 | Product 2 | | |
| Period of shipment | Quantity | Quantity Value | | Value | |
| 2018: | | | | | |
| January-March | | | | | |
| April-June | | | | | |
| July-September | | | | | |
| October-December | | | | | |
| 2019: | | | | | |
| January-March | | | | | |
| April-June | | | | | |
| July-September | | | | | |
| October-December | | | | | |
| 2020: | | | | | |
| January-March | | | | | |
| April-June | | | | | |
| July-September | | | | | |
| October-December | | | | | |
| 2021: | | | | | |
| January-March | | | | | |
| April-June | | _ | | | |

¹ Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your firm's U.S. point of shipment. Please subtract any discounts, rebates, and returns from the quarter in which the sale occurred.

Note.—If your firm's product does not exactly meet the product specifications but is competitive with the specified product, provide a description of the product. Also, please explain any anomalies in your firm's reported pricing data.

| _ | | | | | - 2 | |
|---|----|---|---|----|-----|----|
| D | ro | М | | ct | -1 | |
| г | ıv | u | u | ·ι | - 4 | ١. |

Product 2:

² Pricing product definitions are provided on the first page of Part IV.

| IV-2 c. | Price data checklist Please check that the pricing data in question IV-2(a) has been correctly |
|---------|------------------------------------------------------------------------------------------------|
| | reported. |

| Are the price data reported above: | | | |
|-----------------------------------------------------------------------------------------------|--|--|--|
| In actual dollars (<i>not</i> \$1,000) and pounds? | | | |
| F.o.b. U.S. point of shipment (i.e., does not include U.S. transport costs)? | | | |
| Net of all discounts and rebates? | | | |
| Have discounts, rebates, and returns been credited to the quarter in which the sale occurred? | | | |
| Quantities do not exceed commercial shipments in question II-4 in each year? | | | |
| Explanation(s) for any boxes not checked: | | | |

IV-2d. **Pricing data methodology.--**Please describe the method and the kinds of documents/records that were used to compile your price data.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the price data, as Commission staff may contact your firm regarding questions on the price data. The Commission may also request that your company submit copies of the supporting documents/records (such as sales journal, invoices, etc.) used to compile these data.

| IV-3. | Price | setting.— |
|-------|-------|-----------|
|-------|-------|-----------|

(a) How does your firm determine the prices that it charges for sales of potassium permanganate (*check all that apply*)? If your firm issues price lists, please submit sample pages of a recent list.

| Transaction by transaction | Competitive bid for a specific project | Contracts (other than competitive bid for specific project) | Set price lists | Other | If other, describe |
|----------------------------------|-------------------------------------------------|-------------------------------------------------------------|-----------------------|-------|--------------------|
| | | | | | |

(b) Do your firm's prices for potassium permanganate include lab/field/technical services? If yes, provide the share of your firm's sales in 2020 that included such services and indicate whether your firm provides these services or subcontracts them out.

| No | Yes | Share of quantity of 2020 sales that included lab/field/technical services | Provide services directly | Subcontract out services |
|----|-----|----------------------------------------------------------------------------|------------------------------|--------------------------|
| | | % | | |

(c) Does your firm engage in a bidding process in an attempt to win contracts for the sale of potassium permanganate? If yes, indicate the share of your 2020 sales that were made through a bidding process and describe the process.

| No | Yes | Share of quantity of 2020 sales involving bidding process | Explain the bidding process, including the typical time period, number of rounds of bidding, and whether purchasers typically disclose the names of competing suppliers and/or prices quoted. |
|----|-----|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | % | |

IV-4. <u>Discount policy</u>.--Please indicate and describe your firm's discount policies (*check all that apply*).

| Quantity discounts | Annual total volume discounts | No discount policy | Other | Describe |
|-----------------------|----------------------------------------|--------------------------|-------|----------|
| | | | | |

IV-5. <u>Pricing terms.</u>--On what basis are your firm's prices of domestic potassium permanganate usually quoted *(check one)*?

| Delivered | F.o.b. | If f.o.b., specify point |
|-----------|--------|--------------------------|
| | | |

IV-6. <u>Contract versus spot.</u>--Approximately what share of your firm's sales of its U.S.-produced potassium permanganate in 2020 was on a (1) short-term contract basis, (2) annual contract basis, (3) long-term contract basis, and (4) spot sales basis?

| | Type of sale | | | | | |
|---------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------|--------------------------------------|--------|
| | Short-term contracts (multiple deliveries for less than 12 months) | Annual contracts (multiple deliveries for 12 months) | Long-term contracts (multiple deliveries for more than 12 months) | Spot sales (for a single delivery) | Total (should sum to 100.0% | d o |
| Share of 2020 sales | % | % | % | % | 0.0 | % |

IV-7. <u>Contract provisions.</u>— Please fill out the table regarding your firm's typical sales contracts for U.S.-produced potassium permanganate (or check "not applicable" if your firm does not sell on a short-term, annual and/or long-term contract basis).

| Typical sales contract provisions | Item | Short-term contracts (multiple deliveries for less than 12 months) | Annual contracts (multiple deliveries for 12 months) | Long-term contracts (multiple deliveries for more than 12 months) | |
|----------------------------------------------------|----------------|-----------------------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------|--|
| Average contract duration | No. of days | | 365 | | |
| Price renegotiation (during contract period) | Yes | | | | |
| | No | | | | |
| | Quantity | | | | |
| Fixed quantity and/or price | Price | | | | |
| and, or price | Both | | | | |
| Indexed to raw | Yes | | | | |
| material costs ¹ | No | | | | |
| Not applicable | | | | | |
| ¹ Please identify the indexes used: | | | | | |

IV-8. <u>Lead times.--</u>What is the typical lead time between a customer's order and the date of delivery for your firm's sales of its U.S.-produced potassium permanganate?

| Source | Share of 2020 sales | Lead time (average number of days) |
|------------------------------|---------------------|------------------------------------|
| From inventory | % | |
| Produced to order | % | |
| Total (should sum to 100.0%) | 0.0 % | |

| IV-9. | Shippin | g inform | ation |
|-------|---------|----------|-------|
| | | | |

| (a) | Who generally a | arranges the tr | ansportati | on to your firm | 's customers' | locations? |
|-----|-----------------|-----------------|-------------|-----------------|---------------|------------|
| | Your firm | Purchaser | (check one) | | | |

(b) Indicate the approximate percentage of your firm's sales of potassium permanganate that are delivered the following distances from your firm's production facility.

| Distance from production facility | Share |
|-----------------------------------|-------|
| Within 100 miles | % |
| 101 to 1,000 miles | % |
| Over 1,000 miles | % |
| Total (should sum to 100.0%) | 0.0 % |

IV-10. <u>Geographical shipments.</u>--In which U.S. geographic market area(s) has your firm sold its U.S.-produced potassium permanganate since January 1, 2015 (check all that apply)?

| Geographic area | √ if applicable |
|------------------------------------------------------------------------------------------------------------|-----------------|
| NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT. | |
| Midwest.—IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI. | |
| Southeast.—AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV. | |
| Central Southwest.—AR, LA, OK, and TX. | |
| Mountains.–AZ, CO, ID, MT, NV, NM, UT, and WY. | |
| Pacific Coast.–CA, OR, and WA. | |
| Other .—All other markets in the United States not previously listed, including AK, HI, PR, and VI. | |

| U.S. Pr | oducers' (| Questionr | aire – Pc | tassium Permangan | ate (Fi | ifth R | eview) Page 36 | |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|------------------|------------------------|---------|--------|------------------------------------------------------------------------------|---|
| IV-11. | <u>Inland transportation costs.</u> —What is the approximate percentage of the cost of U.Sproduced potassium permanganate that is accounted for by U.S. inland transportation costs? percent | | | | | | | |
| IV-12. | 2. End uses. Have there been any changes in the end uses of potassium permanganate since January 1, 2015 and/or do you anticipate any future changes? | | | | | | | |
| | No | Yes | If yes, | please describe. | | | | |
| | | | | | | | | |
| IV-13. | Substitu | ites.— | | | | | | |
| | (a) | Can other | product | s be substituted for p | otassi | ium p | ermanganate? | |
| | | ☐ No | | YesPlease fill out t | he tak | ole. | | |
| | | | End | use in which this | | | changes in the price of this substitute the price for potassium permanganate | ? |
| | Substitu | te | | bstitute is used | No | Yes | Explanation | |
| 1. | | | | | | | | |
| 2. | | | | | | | | |
| 3. | | | | | | | | |
| | . , | | d for pot | assium permanganat | | | oes of products that can be uary 1, 2015 and/or do you anticipate | |
| | | No | Yes | If yes, please descri | ibe. | | | |
| | | | | | | | | |
| | | | | | | | | |

| IV-14. | Availability of supply | Has the availability of potassium permanganate in the U.S. marke | t |
|--------|------------------------|------------------------------------------------------------------|---|
| | changed since January | / 1, 2015 and/or do you anticipate any future changes? | |

| Availability in the U.S. market | No | Yes | Please explain, noting the countries and reasons for the changes (e.g., the COVID-19 pandemic, distribution challenges, shipping delays, etc.). |
|------------------------------------|----|-----|-------------------------------------------------------------------------------------------------------------------------------------------------|
| U.Sproduced product | | | |
| Imports from China | | | |
| Imports from all other countries | | | |

IV-15. <u>Demand trends.</u>--Indicate how demand within the United States and outside of the United States (if known) for potassium permanganate has changed since January 1, 2015, and how you anticipate demand will change in the future. Explain any trends and describe the principal factors (e.g., the COVID-19 pandemic) that have affected, and that you anticipate will affect, these changes in demand.

| Market | Overall increase | | Overall decrease | Fluctuate with no clear trend e January 1, | Explanation and factors 2015 | | | |
|---------------------------|------------------|--|------------------|-----------------------------------------------------|------------------------------|--|--|--|
| Within the United States | | | | | | | | |
| Outside the United States | | | | | | | | |
| Anticipated future demand | | | | | | | | |
| Within the United States | | | | | | | | |
| Outside the United States | | | | | | | | |

IV-16. <u>Product changes.</u>—Have there been any significant changes in the product range, product mix, or marketing of potassium permanganate since January 1, 2015 and/or do you anticipate any future changes?

| No | Yes | If yes, please describe. |
|----|-----|--------------------------|
| | | |

| Check al | that a | pply | ' . | | I | ase describe | e, including any change | es since January | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------|------------|------------------------|------------------------------------|---------------------------|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|--|
| | No |) | | | Ski | o to next qu | estion. | | |
| | | | | s cycles (d siness) | e.g. | | | | |
| | | | | istinctive f compet | | | | | |
| permanganate since January 1, 2015 (examples include placing customers on allocation or "controlled order entry," declining to accept new customers or renew existing customers, delivering less than the quantity promised, being unable to meet timely shipment commitments etc.)? If yes, please describe, including the reasons for the constraints (e.g., the COVID-19 pandemic, distribution challenges, shipping delays, etc.). | | | | | | | | | |
| • | | <u> </u> | | | | lays, etc.). | | | |
| No | Ye: | <u> </u> | | , please o | | lays, etc.). | | | |
| No | erials, 2015, | - Indi | If yes | , please o | describe. | | ew material prices have ne future. Explain, noting how price changes have firm's selling prices permanga | raw material affected your for potassium | |
| No Raw mate | erials, 2015, | - Indi | icate how | how pota | describe. ssium pern ct they will | nanganate rachange in the | Explain, noting how price changes have firm's selling prices | raw material affected your for potassium | |

| U.S. Producers | ' Questionnaire – | Potassium | Permanganate | (Fifth Review) |
|----------------|-------------------|-----------|--------------|----------------|
|----------------|-------------------|-----------|--------------|----------------|

| IV-21 | between the U.S. market and alternative country markets. In your discussion, please descriany contracts, other sales arrangements, or other constraints that would prevent or retard firm from shifting potassium permanganate between the U.S. and alternative country mark within a 12-month period. | | | | | | | | | |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|--|--|--|--|--|
| IV-22 | 22. <u>Barriers to trade</u> Are your firm's exports of potassium permanganate subject to any tariff non-tariff barriers to trade in other countries? | | | | | | | | | |
| | No | If yes, please list the countries and describe any such barriers and any significant changes in such barriers that have occurred since January 1, No Yes 2015, or that are expected to occur in the future. | | | | | | | | |
| | | | | | | | | | | |
| IV-23 | countries Please in A F | dicate A, A = the pro E = the pro B = the pro N = the pro | F, S, N, or Coducts from oducts are soducts are soducts are soducts are soducts are | um permanganate produced in the state of the | ne same applications)? ays interchangeable | | | | | |
| | Со | untry-pai | r | China | Other countries | | | | | |
| ι | Jnited State | es | | | | | | | | |
| C | China | | | | | | | | | |
| i | • | able, iden | • • • | potassium permanganate that is suntry-pair and explain the factors | | | | | | |

IV-24. <u>Factors other than price</u>.--Are differences other than price (e.g., quality, availability, transportation network, product range, technical support, *etc.*) between potassium permanganate produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N = such differences are *never* significant

0 = *no familiarity* with products from a specified country-pair

| Country-pair | China | Other countries |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----------------------------|
| United States | | |
| China | | |
| factor in your firm's sales of pota | actors other than price are <i>alway</i> . assium permanganate, identify th es or disadvantages imparted by s | e country-pair and relevant |

| U.S. Producers' Questionnaire – Potassium Permanganate (Fifth Review | U.S. I | Producers' | Questionnaire - | - Potassium | Permanganate ! | (Fifth Review |
|----------------------------------------------------------------------|--------|------------|-----------------|-------------|----------------|---------------|
|----------------------------------------------------------------------|--------|------------|-----------------|-------------|----------------|---------------|

| | Yes— Please impact in the | | _ | No | | Don't know | |
|-----------------|--------------------------------------------------------|--------------------------------------------|----------------------------------------|---------------------------|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| | | | | | | | |
| | Factor | Overall increase | No change | Overall decrease | Fluctuate with no clear trend | Explain, noting how the impos of tariffs under section 301 aff each factor of the potassiu permanganate market in the United States. | fected ım |
| produc | ply of U.S ed potassium manganate | | | | | | |
| perr | of potassium manganate ed from China | | | | | | |
| perr importe | of potassium manganate ed from other ountries | | | | | | |
| | for potassium manganate | | | | | | |
| for | l U.S. demand potassium nanganate | | | | | | |
| рс | iterial costs for otassium manganate | | | | | | |
| | IV that did not pexplanation in t | orovide a n the space p viding the o | arrative r rovided b lata in thi | esponse bo elow. Pleas | x, please not e also use th | ain a response to a question in F e the question number and the is space to highlight any issues y not limited to technical issues w | your |

HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://www.usitc.gov/investigations/701731/2021/potassium_permanganate_china/fif th_review_full.htm

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission for further instructions.

• <u>Upload via Secure Drop Box</u>.—Upload the MS Word questionnaire along with a scanned copy of the signed certification page (page 1) through the Commission's secure upload facility:

Web address: https://dropbox.usitc.gov/oinv/ Pin: PERM

• E-mail.—E-mail the MS Word questionnaire to Nitin.Joshi@usitc.gov; include a scanned copy of the signed certification page (page 1). Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure drop-box system and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm <u>does not </u>**produce this product**, please fill out page 1, print, sign, and submit a scanned copy to the Commission.

<u>Parties to this proceeding</u>.—If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1803). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.